Growth Metrics

Dna X (SONM) Common Equity (2018 - 2025)

Dna X filings provide 8 years of Common Equity readings, the most recent being -$8.0 million for Q4 2025.

  • On a quarterly basis, Common Equity fell 39.56% to -$8.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$8.0 million, a 39.56% decrease, with the full-year FY2025 number at -$8.0 million, down 39.56% from a year prior.
  • Common Equity hit -$8.0 million in Q4 2025 for Dna X, down from -$701000.0 in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $23.1 million in Q3 2023 to a low of -$8.0 million in Q4 2025.
  • Median Common Equity over the past 5 years was $16.4 million (2024), compared with a mean of $12.3 million.
  • Biggest five-year swings in Common Equity: soared 208.74% in 2023 and later plummeted 125.48% in 2024.
  • Dna X's Common Equity stood at $18.6 million in 2021, then grew by 7.6% to $20.0 million in 2022, then grew by 11.59% to $22.4 million in 2023, then plummeted by 125.48% to -$5.7 million in 2024, then crashed by 39.56% to -$8.0 million in 2025.
  • The last three reported values for Common Equity were -$8.0 million (Q4 2025), -$701000.0 (Q3 2025), and -$1.3 million (Q2 2025) per Business Quant data.